[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100287506":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":32,"responsibleParty":46,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"MINOCA",null,"Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).",{"label":13,"type":10,"description":14,"interventionNames":10},"MI-CAD","Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).",{"label":16,"type":10,"description":17,"interventionNames":10},"CATH-NOCA","Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization",[19],{"name":20,"affiliation":21,"role":22},"Harmony R Reynolds, MD","NYU Langone Medical Center","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Jeffrey Berger, MD","CONTACT","212 263 4004","jeffrey.berger@nyumc.org",{"name":20,"role":26,"phone":30,"phoneExt":10,"email":31},"917-693-7070","harmony.reynolds@nyumc.org",[33],{"facility":21,"status":34,"city":35,"state":35,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","New York","10016","United States",{"type":39,"coordinates":40},"Point",[41,42],-74.00597,40.71427,{"lat":42,"lon":41},[45],{"name":25,"role":26,"phone":10,"phoneExt":10,"email":10},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100287506",false,"NCT03022552","Heart Attack Research Program: Platelet Sub-Study (HARP)","Heart Attack Research Program: Platelet Sub-Study (HARP); Platelet Collection for Patients With Myocardial Infarction","HARP","Inclusion Criteria:\n\n* Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms\n* Objective evidence of MI (either or both of the following):\n\n  * Elevation of troponin to above the laboratory upper limit of normal (ULN)\n  * ST segment elevation of ≥1mm on 2 contiguous ECG leads\n* Willing to provide informed consent and comply with all aspects of the protocol\n* Administration of aspirin at least 1 hour before cardiac catheterization\n* Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization\n* Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate\n\nExclusion Criteria:\n\n* Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)\n* Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma\n* Pregnancy\n* Thrombolytic therapy for STEMI (qualifying event)\n* Use of any of the following medications:\n* Platelet antagonists (except aspirin and thienopyridines) within 7 days\n* NSAIDs (e.g., ibuprofen, naproxen) within 3 days.\n* Thrombocytopenia (platelet count \\\u003C100,000)\n* Thrombocytosis (platelet count \\>500,000)\n* Anemia (hemoglobin \\\u003C9 mg\u002Fdl)\n* Hemorrhagic diathesis",true,"FEMALE","21 Years","99 Years",{"count":60,"type":61},350,"ESTIMATED","6 Months","OBSERVATIONAL","This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.",[66],"Myocardial Infarction",[66,68,69,70],"Platelets","Blood Collection","Genomics","2026-04-17",{"date":73,"type":74},"2026-04-20","ACTUAL",{"date":76,"type":74},"2020-07-01",{"date":78,"type":61},"2027-06-30",{"name":5,"class":6},1]